Introduction:
|
Product name
|
Tofacitinib powder
|
|
CAS NO.
|
477600-75-2
|
|
Synonym
|
3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; 3-{(3S,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP 690550
|
|
MW
|
312.3696
|
|
MF
|
C16H20N6O
|
|
Application
|
New oral drugs for the occasional method, (tofacitinib the introduction) to selectively inhibit JAK3 signal transduction pathways in cells, inhibition of CD4 T cell proliferation, further blocking interleukin (IL) 17, a gamma interferon, IL - 6, IL - 8 synthesis and secretion of cytokines, such as inhibition of patients with RA synovial fibroblasts proliferation and damaged cartilage further damage.Jak kinase inhibitors, the treatment of rheumatoid arth
|
|
Standard
|
purity:>99%
|
|
Appearance
|
White powder
|
|
Shelf life
|
2 yares
|
Tofacitinib (INN) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer. Tofacitinib is marketed as Xeljanz and Jakvinus.
It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and other countries.
It has demonstrated effectiveness in the treatment of psoriasis in Phase 3 studies. It is being studied for treatment of inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.
Function:
It is an inhibitor of the enzyme janus kinase 1 (JAK1) and janus kinase 3 (JAK 3) , which means that it interferes with the JAK-STAT signaling pathway, which transmits extracellular information into the cell nucleus, influencingDNA transcription.
In a mouse model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.
Usage:
Rheumatoid arthritis
Phase II clinical trials tested the drug in rheumatoid arthritis patients that had not responded to DMARD therapy. In a tofacitinib monotherapy study, theACR score improved by at least 20% (ACR-20) in 67% of patients versus 25% who received placebo; and a study that combined the drug with methotrexateachieved ACR-20 in 59% of patients versus 35% who received methotrexate alone.
Psoriasis
Tofacitinib is a current investigational drug in psoriasis. Tofacitinib has demonstrated its effectiveness for plaque psoriasis in Phase 3 randomized, controlled trials in comparison to placebo and to etanercept.In particular, a 10 mg twice-daily dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly.
Ulcerative colitis
The phase 3 OCTAVE study of Tofacitinib in ulcerative colitis started in 2012 and completed in 2015.
Vitiligo
In a June 2015 case report, a 53-year-old woman with vitiligo showed noticeable improvement after taking tofacitinib for five months.
Atopic dermatitis
The results of using Tofacitinib in 6 patients with recalcitrant atopic dermatitis was published in the September 2015. All saw improvement in their atopic dermatitis without any adverse events.
Specification:
|
TEST
|
SPECIFICATION
|
RESULT
|
|
Character
|
White to off-white powder
|
White powder
|
|
Identification
|
A. Infrared absorption
B. The retention time of major peak of sample
corresponds to that of reference standard
|
Conforms
Conforms
|
|
Loss on drying
|
≤0.8%
|
0.32%
|
|
Residue on Ignition
|
≤0.1%
|
0.03%
|
|
Related compounds
|
Impurity A≤0.2%
Impurity B≤0.3%
Impurity C≤1.0%
Any other impurity≤1.0%
|
0.02%
0.04%
0.06%
0.04%
|
|
Residual Solvents
|
Methanol≤0.3%
Acetonum≤0.5%
Methylencdichloride≤0.06%
MTBE≤0.5%
Ethyl acetate≤0.5%
Methylbenzene≤0.089%
|
ND
ND
ND
ND
0.12%
ND
|
|
Assay
|
98.0%~101.5%
|
99.11%
|
|
Packaging and storage
|
Preserve in well-closed container store at controlled room temperature.
|
|
Conclusion
|
All the results conform to the requirement of BP2010.
|
Advantages:
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.
1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.
2 . Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.
3 . Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate
4 . Warm after-sale service Any of your question would be solved for the first as soon as possible.
Tofacitinib CAS 477600-75-2 Pharmaceutical Raw Materials
Tofacitinib CAS 477600-75-2 Pharmaceutical Intermediate
Tofacitinib CAS 477600-75-2 Raw Chemical Product
Tofacitinib CAS 477600-75-2 Supplier & manufactuer
China
